Department of Ophthalmology, Byers Eye Institute, Mary M. and Sash A. Spencer Center for Vision Research, Stanford University School of Medicine, Palo Alto, California 94034.
Department of Neurosurgery, F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts 02115.
eNeuro. 2024 Mar 28;11(3). doi: 10.1523/ENEURO.0478-23.2024. Print 2024 Mar.
Neuroprotection after injury or in neurodegenerative disease remains a major goal for basic and translational neuroscience. Retinal ganglion cells (RGCs), the projection neurons of the eye, degenerate in optic neuropathies after axon injury, and there are no clinical therapies to prevent their loss or restore their connectivity to targets in the brain. Here we demonstrate a profound neuroprotective effect of the exogenous expression of various Ca/calmodulin-dependent protein kinase II (CaMKII) isoforms in mice. A dramatic increase in RGC survival following the optic nerve trauma was elicited by the expression of constitutively active variants of multiple CaMKII isoforms in RGCs using adeno-associated viral (AAV) vectors across a 100-fold range of AAV dosing in vivo. Despite this neuroprotection, however, short-distance RGC axon sprouting was suppressed by CaMKII, and long-distance axon regeneration elicited by several pro-axon growth treatments was likewise inhibited even as CaMKII further enhanced RGC survival. Notably, in a dose-escalation study, AAV-expressed CaMKII was more potent for axon growth suppression than the promotion of survival. That diffuse overexpression of constitutively active CaMKII strongly promotes RGC survival after axon injury may be clinically valuable for neuroprotection per se. However, the associated strong suppression of the optic nerve axon regeneration demonstrates the need for understanding the intracellular domain- and target-specific CaMKII activities to the development of CaMKII signaling pathway-directed strategies for the treatment of optic neuropathies.
神经保护是基础和转化神经科学的主要目标之一,无论是在损伤后还是在神经退行性疾病中。在外伤性视神经病变中,视网膜神经节细胞(RGC)作为眼的投射神经元,其轴突会发生变性,而目前还没有临床疗法可以预防其丢失或恢复其与大脑靶目标的连接。在这里,我们展示了外源性表达各种钙/钙调蛋白依赖性蛋白激酶 II(CaMKII)异构体在小鼠中的显著神经保护作用。使用腺相关病毒(AAV)载体,通过在体内进行 100 倍范围的 AAV 给药,使多种 CaMKII 异构体的组成性激活变体在 RGC 中表达,从而引发 RGC 存活的显著增加。然而,尽管有这种神经保护作用,但 CaMKII 抑制了短距离 RGC 轴突的发芽,而几种促进轴突生长的治疗方法引发的长距离轴突再生也被抑制,即使 CaMKII 进一步增强了 RGC 的存活。值得注意的是,在剂量递增研究中,AAV 表达的 CaMKII 在抑制轴突生长方面比促进存活更为有效。弥漫性过表达组成性激活的 CaMKII 在轴突损伤后强烈促进 RGC 存活,这可能对神经保护本身具有临床价值。然而,视神经轴突再生的强烈抑制表明,需要了解细胞内结构域和靶标特异性 CaMKII 活性,以制定针对神经退行性疾病的 CaMKII 信号通路导向治疗策略。